Silintan is a dietary supplement marketed as a treatment for joint and body aches. According to a recent analysis by the FDA, however, all lots contained undeclared meloxicam, creating an increased risk of adverse events.

The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed. 

This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions. 

This product was distributed throughout the United States from April 2022 to December 2025. Customers have been warned to stop taking it immediately. 

Medtronic's MiniMed Go technology was designed to deliver real-time health data and recommendations to patients with type 1 and type 2 diabetes. It works with the Instinct sensors designed by Abbott.

Financial literacy is no longer optional for physicians. “If you're not financially viable, you can't function,” explained Nirat Beohar, MD. “The business education is probably just as important as learning a new procedure.”

The two vendors involved say supplies of PYP and HDP could be disrupted for months.

A new comprehensive report detailed the latest stats and trends in hypertension, coronary heart disease, stroke and many other areas of interest. “Progress in cardiovascular health depends on knowing where we stand,” the authors wrote. “To improve, we must measure—not occasionally, but consistently, transparently and with purpose.”

The newest addition to the company's Farapulse PFA Platform was specifically approved to perform cavotricuspid isthmus ablation. 

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?